Related Experiment Video

Updated: Aug 1, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K

Covert hepatic encephalopathy is associated with aggressive disease progression and poor survival in patients with

Jian Wang1, Ming Jie Deng1, Pei Mei Shi1

  • 1Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.

Journal of Digestive Diseases
|December 18, 2023
PubMed

Insights

Covert hepatic encephalopathy (CHE) in liver cirrhosis patients is linked to worse disease progression and lower survival rates. Early detection of CHE is crucial for predicting poor outcomes in these individuals.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Clinical Medicine

Background:

  • Covert hepatic encephalopathy (CHE) negatively impacts quality of life and increases overt hepatic encephalopathy (OHE) risk in cirrhosis patients.
  • The long-term prognostic implications of CHE in cirrhosis remain under investigation.

Purpose of the Study:

  • To investigate the association between CHE and disease progression, including ascites exacerbation and portal vein thrombosis (PVT).
  • To explore the impact of CHE on overall survival in patients with liver cirrhosis.

Main Methods:

  • A single-center prospective study involving 132 hospitalized cirrhosis patients.
  • Diagnosis of CHE was performed using the validated Chinese standardized psychometric hepatic encephalopathy score.
  • Average follow-up duration was approximately 45 months.

Main Results:

  • CHE was identified in 35.61% of patients.
  • CHE was associated with a higher risk of OHE, ascites exacerbation, and PVT.
  • Patients with CHE exhibited significantly lower survival rates and CHE was an independent predictor of mortality.

Conclusions:

  • CHE is significantly associated with disease progression in cirrhosis patients.
  • CHE serves as an independent predictor of poor prognosis and reduced survival in liver cirrhosis.
Abstract

Keywords:
cirrhosiscirrhosis-related complicationscovert hepatic encephalopathymortalitypsychometric hepatic encephalopathy score

More Related Videos

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

1.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...